Alexza Pharmaceuticals Alexza Pharmaceuticals

About

Alexza Pharmaceuticals is a technologically advanced, forward-thinking and innovative company based in Fremont, California. We are focused on the research and development of novel, proprietary products for the acute treatment of underserved medical needs.

Ferrer is Alexza’s Parent Company. At Ferrer, we make a positive impact in society and meet the highest standards of social and environmental performance, transparency, and corporate responsibility in every territory with a direct presence. That is why in 2022 we became a B Corp company.

To fulfill our purpose, we offer transformative therapeutic solutions with an increasing focus on pulmonary vascular and interstitial lung diseases and neurological disorders. We comply with all the legislation and regulations applicable to our work and as a member of several sectoral associations in various countries, we also meet the requirements included in the respective codes of ethics and self-regulation in all the countries in which we have a presence.

Founded in Barcelona in 1959, our products are present in more than a hundred countries, and we have a team of over 1,800 people. Professionals that we empower and accompany in their learning and wellbeing so that they are proud of working at Ferrer. For more Information visit, Ferrer.

ferrer for good logo

Corporate History

2000
Founded by Dr. Alejandro Zaffaroni
2006
IPO
2011
Ferrer Partnership ADASUVE
2012
ADASUVE approval (FDA)
2013
Icon
ADASUVE approval (EMA)
2016
Icon
Aquired by Ferrer
2017
Pipeline Expansion
2019
Staccato apomorphone
2020
UCB Partnership Staccato alprazolam
2021
Staccato granisetron

Alexza develops products with rapid onset of effect, ease of use, non-invasive administration and dosage titration. Our products are commercialized through commercial partners worldwide.

We are dedicated to:

  • Designing innovative and proprietary products
  • Developing treatments for acute and intermittent conditions
  • Finding new therapeutic solutions for conditions that would benefit from rapid, reliable and non-invasive treatment
  • Providing solutions to treat conditions that other forms of delivery cannot treat effectively
  • Developing products with patients and physicians in mind

Learn more about our development programs

The Staccato OBT system is a hand-held inhaler designed to deliver a pure drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner. This platform has the potential to address unmet needs and provides flexibility
to deliver the most important pharmaceutical benefits in an innovative way.

Learn more about Staccato OBT

ADASUVE® is Alexza’s first commercial product. ADASUVE is approved for marketing in the United States, Europe (through centralized procedure) and a number of Latin American countries. ADASUVE is commercially available through our partners in 23 countries.

To learn more and for full prescribing information, including boxed warning, visit ADASUVE.com or the EMA website.

Adasuve (loxapine) inhalation powder logo
Staccato OBT Staccato Logo